Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 18/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476053 | 0.91 | ERBB2 (0.66) | EGFRERBB2BRAF | |
| SCHEMBL23750174 | 0.86 | ERBB2 (0.79) | EGFRERBB2BRAF | |
| SCHEMBL30575962 | 0.86 | ERBB2 (0.79) | EGFRERBB2BRAF | |
| SCHEMBL31476056 | 0.85 | EGFR (0.63) | EGFRERBB2BRAF | |
| SCHEMBL31475844 | 0.84 | EGFR (0.57) | EGFRERBB2BRAF | |
| SCHEMBL26418909 | 0.83 | ERBB2 (0.66) | EGFRERBB2BRAF | |
| SCHEMBL31475799 | 0.82 | EGFR (0.55) | EGFRERBB2BRAF | |
| SCHEMBL31475915 | 0.82 | EGFR (0.53) | EGFRERBB2BRAF | |
| SCHEMBL24809529 | 0.81 | ERBB2 (0.54) | EGFRERBB2BRAF | |
| SCHEMBL31476191 | 0.81 | EGFR (0.53) | EGFRERBB2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885BRAF 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.